The CerK inhibitor NVP-231 blocks the M phase of the cell cycle and activates the caspase-9/caspase-3 pathway to promote apoptosis in lung cancer cells, while the overexpression of CerK promotes cell proliferation and protects lung cancer cells from apoptosis [22]. Here, CASP3 is linked to lung carcinoma.